A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice
Respiratory syncytial virus (RSV) is a common infection in infancy, with nearly all children affected by two years of age. Approximately 0.5% to 2.0% of all children are hospitalized with lower respiratory tract disease, of which 50% to 90% have bronchiolitis and 5% to 40% have pneumonia. Morbidity...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2011/493056 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849306003972030464 |
|---|---|
| author | Bosco A Paes Ian Mitchell Anna Banerji Krista L Lanctôt Joanne M Langley |
| author_facet | Bosco A Paes Ian Mitchell Anna Banerji Krista L Lanctôt Joanne M Langley |
| author_sort | Bosco A Paes |
| collection | DOAJ |
| description | Respiratory syncytial virus (RSV) is a common infection in infancy, with nearly all children affected by two years of age. Approximately 0.5% to 2.0% of all children are hospitalized with lower respiratory tract disease, of which 50% to 90% have bronchiolitis and 5% to 40% have pneumonia. Morbidity and mortality are highest in children with nosocomial infection and in those with underlying medical illnesses such as cardiac and chronic lung disease. Aboriginal children residing in remote northern regions are specifically considered to be at high risk for hospitalization due to RSV infection. Thorough hand washing and health education are the principal strategies in primary prevention. In the absence of a vaccine, palivizumab prophylaxis is currently the best intervention to reduce the burden of illness and RSV-related hospitalization in high-risk children. Health care professionals should provide palivizumab prophylaxis cost effectively in accordance with recommendations issued by pediatric societies and national advisory bodies. |
| format | Article |
| id | doaj-art-30c97b28dacf4cec92bdc41adfce4887 |
| institution | Kabale University |
| issn | 1198-2241 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-30c97b28dacf4cec92bdc41adfce48872025-08-20T03:55:12ZengWileyCanadian Respiratory Journal1198-22412011-01-01182e10e1910.1155/2011/493056A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical PracticeBosco A Paes0Ian Mitchell1Anna Banerji2Krista L Lanctôt3Joanne M Langley4Department of Pediatrics, McMaster University, Hamilton, Ontario, CanadaDivision of Respirology, Department of Pediatrics, Alberta Children’s Hospital and University of Calgary, Calgary, Alberta, CanadaPediatric Infectious Disease, St Michael’s Hospital, CanadaMedical Outcomes and Research in Economics (MORE) Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, CanadaDepartment of Pediatrics, Clinical Trials Research Centre, Dalhousie University and IWK Health Centre, Halifax, Nova Scotia, CanadaRespiratory syncytial virus (RSV) is a common infection in infancy, with nearly all children affected by two years of age. Approximately 0.5% to 2.0% of all children are hospitalized with lower respiratory tract disease, of which 50% to 90% have bronchiolitis and 5% to 40% have pneumonia. Morbidity and mortality are highest in children with nosocomial infection and in those with underlying medical illnesses such as cardiac and chronic lung disease. Aboriginal children residing in remote northern regions are specifically considered to be at high risk for hospitalization due to RSV infection. Thorough hand washing and health education are the principal strategies in primary prevention. In the absence of a vaccine, palivizumab prophylaxis is currently the best intervention to reduce the burden of illness and RSV-related hospitalization in high-risk children. Health care professionals should provide palivizumab prophylaxis cost effectively in accordance with recommendations issued by pediatric societies and national advisory bodies.http://dx.doi.org/10.1155/2011/493056 |
| spellingShingle | Bosco A Paes Ian Mitchell Anna Banerji Krista L Lanctôt Joanne M Langley A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice Canadian Respiratory Journal |
| title | A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice |
| title_full | A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice |
| title_fullStr | A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice |
| title_full_unstemmed | A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice |
| title_short | A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice |
| title_sort | decade of respiratory syncytial virus epidemiology and prophylaxis translating evidence into everyday clinical practice |
| url | http://dx.doi.org/10.1155/2011/493056 |
| work_keys_str_mv | AT boscoapaes adecadeofrespiratorysyncytialvirusepidemiologyandprophylaxistranslatingevidenceintoeverydayclinicalpractice AT ianmitchell adecadeofrespiratorysyncytialvirusepidemiologyandprophylaxistranslatingevidenceintoeverydayclinicalpractice AT annabanerji adecadeofrespiratorysyncytialvirusepidemiologyandprophylaxistranslatingevidenceintoeverydayclinicalpractice AT kristallanctot adecadeofrespiratorysyncytialvirusepidemiologyandprophylaxistranslatingevidenceintoeverydayclinicalpractice AT joannemlangley adecadeofrespiratorysyncytialvirusepidemiologyandprophylaxistranslatingevidenceintoeverydayclinicalpractice AT boscoapaes decadeofrespiratorysyncytialvirusepidemiologyandprophylaxistranslatingevidenceintoeverydayclinicalpractice AT ianmitchell decadeofrespiratorysyncytialvirusepidemiologyandprophylaxistranslatingevidenceintoeverydayclinicalpractice AT annabanerji decadeofrespiratorysyncytialvirusepidemiologyandprophylaxistranslatingevidenceintoeverydayclinicalpractice AT kristallanctot decadeofrespiratorysyncytialvirusepidemiologyandprophylaxistranslatingevidenceintoeverydayclinicalpractice AT joannemlangley decadeofrespiratorysyncytialvirusepidemiologyandprophylaxistranslatingevidenceintoeverydayclinicalpractice |